Literature DB >> 1730743

TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector.

S P Wu1, D Theodorescu, R S Kerbel, J K Willson, K M Mulder, L E Humphrey, M G Brattain.   

Abstract

Transforming growth factor-beta 1 (TGF-beta 1) has previously been implicated as a potential negative autocrine or paracrine growth regulator of certain cell types (Arteaga, C. L., R. J. Coffey, Jr., T. C. Dugger, C. M. McCutchen, H. L. Moses, and R. M. Lyons. 1990. Cell Growth & Differ. 1:367-374; Hafez, M. M., D. Infante, S. Winawer, and E. Friedman. 1990. Cell Growth & Differ. 1:617-626; Glick, A. B., K. C. Flanders, D. Danielpour, S. H. Yuspa, and M. B. Sporn. 1989. Cell Regulation. 1:87-97). This is based mainly on experiments assessing the effects of exogenous TGF-beta 1 or neutralizing antibodies to TGF-beta 1 on normal or tumor cell proliferation in vitro. However, direct evidence demonstrating such a negative regulation of tumor cell growth in vivo is still lacking. To overcome this problem we have constructed and used an antisense expression vector for TGF-beta 1 as a means of regulating endogenous TGF-beta 1 expression in tumor cells. Antisense-transfected FET human colon carcinoma cells showed a fivefold reduction in TGF-beta 1 mRNA and 15-fold reduction in TGF-beta 1 secretion. Antisense mRNA was detected in transfected cells by an RNase protection assay. Compared to control cells, cultured antisense-transfected cells showed a reduction in lag phase time rather than a change in doubling time. Cloning efficiencies of transfected cells were four times greater than control cells in anchorage-independent assays. Control cells did not form tumors at 5 x 10(5) in athymic nude mice. Antisense-transfected cells formed tumors in 40% of animals injected. At higher inocula (1 x 10(6) cells) antisense-transfected cells formed tumors in 100% of animals injected, but control cells still failed to form tumors. These results show that TGF-beta 1 acts as a negative growth regulator of human colon carcinoma cells in vivo as well as in vitro. Acquisition of partial or full resistance to such inhibitory effects may therefore contribute to tumor development and progression.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1730743      PMCID： PMC2289262          DOI： 10.1083/jcb.116.1.187

Source DB:  PubMed          Journal:  J Cell Biol        ISSN： 0021-9525            Impact factor:   10.539


  39 in total

1.  Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines.

Authors:  I Chantret; A Barbat; E Dussaulx; M G Brattain; A Zweibaum
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

2.  Effects of growth stimulatory factors on mitogenicity and c-myc expression in poorly differentiated and well differentiated human colon carcinoma cells.

Authors:  K M Mulder; M G Brattain
Journal:  Mol Endocrinol       Date:  1989-08

3.  Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells.

Authors:  R Khokha; P Waterhouse; S Yagel; P K Lala; C M Overall; G Norton; D T Denhardt
Journal:  Science       Date:  1989-02-17       Impact factor: 47.728

4.  A highly modular cloning vector for the analysis of eukaryotic genes and gene regulatory elements.

Authors:  D S Pfarr; G Sathe; M E Reff
Journal:  DNA       Date:  1985-12

5.  Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1.

Authors:  N M Hoosein; M K McKnight; A E Levine; K M Mulder; K E Childress; D E Brattain; M G Brattain
Journal:  Exp Cell Res       Date:  1989-04       Impact factor: 3.905

6.  Different epidermal growth factor growth responses and receptor levels in human colon carcinoma cell lines.

Authors:  C W Wan; M K McKnight; D E Brattain; M G Brattain; L C Yeoman
Journal:  Cancer Lett       Date:  1988-12-01       Impact factor: 8.679

7.  Alterations in c-myc expression in relation to maturational status of human colon carcinoma cells.

Authors:  K M Mulder; M G Brattain
Journal:  Int J Cancer       Date:  1988-07-15       Impact factor: 7.396

8.  Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose.

Authors:  D D Boyd; A E Levine; D E Brattain; M K McKnight; M G Brattain
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

9.  Human transforming growth factor-beta 3: recombinant expression, purification, and biological activities in comparison with transforming growth factors-beta 1 and -beta 2.

Authors:  J L Graycar; D A Miller; B A Arrick; R M Lyons; H L Moses; R Derynck
Journal:  Mol Endocrinol       Date:  1989-12

10.  Immunodetection and modulation of cellular growth with antibodies against native transforming growth factor-beta 1.

Authors:  J Keski-Oja; R M Lyons; H L Moses
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701
View more
  41 in total

1.  TGFβ and Hippo Pathways Cooperate to Enhance Sarcomagenesis and Metastasis through the Hyaluronan-Mediated Motility Receptor (HMMR).

Authors:  Shuai Ye; Ying Liu; Ashley M Fuller; Rohan Katti; Gabrielle E Ciotti; Susan Chor; Md Zahidul Alam; Samir Devalaraja; Kristin Lorent; Kristy Weber; Malay Haldar; Michael A Pack; T S Karin Eisinger-Mathason
Journal:  Mol Cancer Res       Date:  2020-01-27       Impact factor: 5.852

2.  Proliferation of mutators in A cell population.

Authors:  E F Mao; L Lane; J Lee; J H Miller
Journal:  J Bacteriol       Date:  1997-01       Impact factor: 3.490

3.  HLTF gene silencing in human colon cancer.

Authors:  Helen R Moinova; Wei-Dong Chen; Lanlan Shen; Dominic Smiraglia; Joseph Olechnowicz; Lakshmeswari Ravi; Lakshmi Kasturi; Lois Myeroff; Christoph Plass; Ramon Parsons; John Minna; James K V Willson; Sylvan B Green; Jean-Pierre Issa; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

4.  15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.

Authors:  Min Yan; Ronald M Rerko; Petra Platzer; Dawn Dawson; Joseph Willis; Min Tong; Earl Lawrence; James Lutterbaugh; Shilong Lu; James K V Willson; Guangbin Luo; Jack Hensold; Hsin-Hsiung Tai; Keith Wilson; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

5.  Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion.

Authors:  A B Glick; A B Kulkarni; T Tennenbaum; H Hennings; K C Flanders; M O'Reilly; M B Sporn; S Karlsson; S H Yuspa
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.

Authors:  Chunguang Guo; Jerome F Sah; Lydia Beard; James K V Willson; Sanford D Markowitz; Kishore Guda
Journal:  Genes Chromosomes Cancer       Date:  2008-11       Impact factor: 5.006

7.  Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha.

Authors:  C A Carvajal; A A Herrada; C R Castillo; F J Contreras; C B Stehr; L M Mosso; A M Kalergis; C E Fardella
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

8.  Interactions between interferon gamma and retinoic acid with transforming growth factor beta in the induction of immune recognition molecules.

Authors:  R Darley; A Morris; J Passas; W Bateman
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

9.  Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.

Authors:  L M Weiskirch; Y Bar-Dagan; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

10.  Integration of transforming growth factor beta and RAS signaling silences a RAB5 guanine nucleotide exchange factor and enhances growth factor-directed cell migration.

Authors:  Hailiang Hu; Marc Milstein; Joanne M Bliss; Minh Thai; Gautam Malhotra; Lucia C Huynh; John Colicelli
Journal:  Mol Cell Biol       Date:  2007-12-26       Impact factor: 4.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.